seragy secures €12 million mixed financing for biomarkers
Debt, equity and public funding support expanded laboratory capabilities in Hanover.
seragy announced €12 million in financing on October 14, backed by Commerzbank, MBG Niedersachsen and the State of Lower Saxony. The package combines debt, equity and public funding; allocations were not disclosed.
Proceeds support development of its SeRAS biomarker platform, laboratory expansion and team growth. The technology measures protein aggregation to inform research into neurodegenerative diseases.
The company also received separate Michael J. Fox Foundation funding for a Parkinson’s assay. That grant is distinct from the €12 million financing package.
Use of funds
Develop SeRAS quantitative biomarker platform
Expand Hanover laboratory and analytical capabilities
Grow team and international collaborations